API manufacturer 16789-98-3 Desmopressin Acetate CAS NO.16789-98-3

description

desmopressin is used to treat nocturnal enuresis (bedwetting). it is usually prescribed in the form of oral desmopressin acetate, ddavp. children taking ddavp have 2.2 fewer wet nights per week and are 4.5 times more likely to sleep without disruption compared with placebo.

us drug regulators banned treating nocturnal enuresis with desmopressin nasal sprays after two patients died and fifty-nine other patients suffered seizures. the patients were using desmopressin when they developed hyponatremia, an imbalance of the body's sodium levels.

nighttime urination
desmopressin has some benefit in adults who have problems with night time urination (known as nocturia).
clotting disorders desmopressin (ddavp) stimulates the release of von willebrand factor (vwf) from the weibel-palade_body bodies ofendothelial cells, thereby increasing the levels of vwf (as well as coagulant factor viii) 3 to 5-fold. desmopressin can be used to promote the release of von willebrand factor (with subsequent increase in factor viii survival secondary to vwf complexing) in patients with coagulation disorders such as von willebrand disease, mild hemophilia a (factor viii deficiency), and thrombocytopenia. it can be used with uremic induced platelet dysfunction. it is not effective in the treatment of hemophilia b (factor ix deficiency) or severe hemophilia a.
diabetes insipidus
desmopressin is used in the treatment of central diabetes insipidus (di), to replace endogenous antidiuretic hormone(adh) that is missing in the central nervous system type of this disorder (decreased production of adh from the posterior pituitary). it is also used in the diagnostic workup for diabetes insipidus, in order to distinguish central from nephrogenic di.